Epilepsy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Epilepsy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Epilepsy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Epilepsy Market by downloading the comprehensive report from DelveInsight @ Epilepsy Treatment Market Size
Key Takeaways from the Epilepsy Market Report
- In October 2024:- A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy. The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
- In October 2024:- Jazz Pharmaceuticals- A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution. This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
- In October 2024:- Hoffmann-La Roche- The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
- As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of epilepsy were nearly 7 million in the 7MM. These cases are projected to increase due to the increased aging global population where older adults are more susceptible to conditions such as stroke, dementia, and epilepsy during the forecast period (2024-2034).
- In 2023, among the 7MM, the US accounted for approximately 3 million total diagnosed prevalent cases of epilepsy, of which nearly 14% of cases were diagnosed in children and 86% in adults; the total cases of epilepsy are expected to increase by 2034.
- The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.
- The leading Epilepsy Companies such as Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
- Promising Epilepsy Therapies such as Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.
Gain a competitive edge in the Epilepsy Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Epilepsy Treatment Drugs
Epilepsy Epidemiology Segmentation in the 7MM
- Total Diagnosed Prevalent Cases
- Gender-specific Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases of Epilepsy Based on Seizure Type
- Diagnosed Cases of Other Types of Epilepsies and Associated Diseases
Epilepsy Treatment Market
The Epilepsy treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case. Epilepsy treatment involves various drug classes to control seizures, including sodium channel blockers (e.g., phenytoin, lamotrigine), which stabilize neuronal activity by inhibiting abnormal electrical impulses. Calcium channel blockers (e.g., ethosuximide) are effective for absence seizures, while GABAergic agents (e.g., valproate, benzodiazepines) enhance inhibitory neurotransmission to reduce seizure frequency. Newer-generation AEDs like levetiracetam and topiramate offer broader efficacy with fewer side effects, addressing both generalized and focal seizures. Non-pharmacological options such as vagus nerve stimulation (VNS) and the ketogenic diet are also utilized, particularly in drug-resistant cases, providing additional therapeutic avenues.
Discover key developments and opportunities in the Epilepsy Market. Click here to learn more from DelveInsight’s latest report @ Epilepsy Market Size
Epilepsy Marketed Drugs
- LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
- EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals
- XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical
- AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis
Epilepsy Emerging Drugs
- XEN1101/Azetukalner: Xenon Pharmaceuticals
- Soticlestat (TAK-935): Takeda/Ovid Therapeutics
Epilepsy Market Outlook
The treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case.
Download DelveInsight’s Epilepsy Market report today and stay ahead in this rapidly evolving field. @ Epilepsy Clinical Trials
Scope of the Epilepsy Market Report
- Coverage- 7MM
- Epilepsy Companies- Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
- Epilepsy Therapies- Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.
- Epilepsy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement
Download the report to understand which factors are driving Epilepsy Market Trends @ Epilepsy Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Epilepsy Market Overview at a Glance
4 Methodology of Epilepsy Epidemiology and Market
5 Executive Summary
6 Key Events
7 Disease Background and Overview
8 Epilepsy Patient Journey
9 Epilepsy Epidemiology and Patient Population
10 Epilepsy Marketed Drugs
11 Epilepsy Emerging Drugs
12 Epilepsy: Market Analysis
13 Key Opinion Leaders’ Views
14 SWOT Analysis
15 Epilepsy Unmet Needs
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Epilepsy Treatment Market Size in the 7MM was ~USD 9 billion in 2023, estimated DelveInsight